Periocular Sweat Glands and Syringomas

Haus Of Ästhetik
Jan 7
5 min read

Apocrine and eccrine glands are specialised sweat glands with distinct anatomy, physiology, and clinical relevance. Syringomas are not sweat glands and are not the same as apocrine or eccrine glands. They are benign adnexal tumours arising from the ductal component of eccrine sweat glands. This distinction is particularly important in the periocular and eyelid region, where syringomas are most commonly encountered and most frequently misinterpreted.

Why the eyelids are uniquely affected

The periocular region has several anatomical features that predispose it to visible syringoma formation:

• Very high density of eccrine sweat glands

• Exceptionally thin epidermis and dermis

• Tight adherence of skin to the orbicularis oculi muscle

• Limited dermal volume for lateral lesion expansion

As a result, even small eccrine duct proliferations become clinically apparent on the eyelids, typically presenting as multiple small papules clustered along the lower eyelids and upper malar region.

Eccrine sweat glands in the periocular region

Anatomy and function

Eccrine glands are distributed throughout eyelid and periocular skin. Each gland consists of a coiled secretory unit in the deep dermis connected to the skin surface by a straight duct. Their primary function is thermoregulation, producing a watery, electrolyte-rich sweat under cholinergic sympathetic control. In the eyelids, eccrine activity also contributes to local hydration and barrier function.

Clinical relevance

Eccrine glands are implicated in:

• Primary and secondary hyperhidrosis

• Eccrine duct tumours, including syringomas

Apocrine glands and the eye area

Apocrine glands are present in modified form around the eyelids, including the glands of Moll.

Anatomy and function

Apocrine glands are larger, hormonally responsive glands whose ducts usually empty into hair follicles. Their protein- and lipid-rich secretions are not involved in thermoregulation and are not the origin of syringomas.

Clinical relevance

Apocrine glands are associated with apocrine cysts and rare apocrine tumours of the eyelid but should not be conflated with eccrine-derived lesions.

What are periocular syringomas?

Periocular syringomas are benign eccrine duct tumours that develop within the dermis of the eyelids.

Pathophysiology

They arise from proliferation of eccrine duct epithelial cells, forming small duct-like structures embedded within a dense fibrotic stroma. Syringomas are non-inflammatory, non-infectious, and have no malignant potential.

Clinical appearance

• Firm, flesh-coloured to yellow papules

• Typically 1–3 mm in diameter

• Symmetrical distribution, most often on the lower eyelids

Their dermal depth explains resistance to surface-level treatments.

Hormonal and biological influences

Periocular syringomas frequently become more prominent during periods of hormonal change, including puberty, pregnancy, and perimenopause. Hormonal modulation of eccrine duct activity is thought to contribute to lesion proliferation and explains the strong female predominance.

Differential diagnosis of periocular papules

Several periocular lesions may resemble syringomas clinically:

• Milia, which are superficial keratin cysts

• Xanthelasma, characterised by yellow lipid-rich plaques

• Sebaceous hyperplasia, which shows central umbilication

• Acneiform eruptions, which are inflammatory and transient

Syringomas are distinguished by their dermal depth, firmness, symmetry, and lack of response to topical therapies.

Histology and clinical correlation

Histologically, syringomas demonstrate characteristic comma-shaped or tadpole-like eccrine ducts lined by two layers of epithelial cells within a sclerotic stroma. This architecture explains:

• Limited response to topical agents and chemical peels

• High recurrence rates following destructive treatments

• The need for conservative, depth-controlled intervention

Management principles for periocular syringomas

Syringomas are benign and do not require treatment unless cosmetically concerning.

Conservative-first approach

The eyelids are a high-risk aesthetic zone. Over-treatment carries a significant risk of post-inflammatory hyperpigmentation, textural change, scarring, and eyelid contour alteration. Observation is therefore often the most appropriate strategy.

Interventional options

Where treatment is pursued, goals should be limited to improvement rather than eradication.

• Conservative ablative laser therapy

• Electrosurgical destruction in selected cases

• Surgical excision for isolated lesions only

Recurrence is common regardless of modality, and this must be discussed in advance.

Do periocular syringomas change in size or appearance?

Syringomas are structurally stable, benign dermal lesions and do not rapidly grow or shrink. However, it is common for patients to notice that they appear more prominent or swollen at certain times. This reflects changes in the surrounding periocular tissue rather than true enlargement of the syringomas themselves.

The eyelid skin is exceptionally thin and highly sensitive to fluid shifts. Factors such as periorbital oedema from poor sleep, dietary salt intake, alcohol consumption, allergies, or systemic illness can temporarily accentuate the contour of underlying dermal lesions. Heat exposure, exercise, or emotional stress may also increase local vasodilation and eccrine activity, making syringomas more noticeable.

Hormonal fluctuations play an additional role. Many patients report increased prominence during the menstrual cycle, pregnancy, or perimenopause. These periods are associated with changes in eccrine duct activity and local tissue hydration, which can exaggerate the appearance of existing lesions without indicating disease progression.

Importantly, true growth or increase in number of syringomas occurs slowly over months or years, not day to day. Sudden or short-term changes in appearance should therefore be understood as physiological variation rather than pathological change. Recognising this helps avoid unnecessary anxiety and reduces the risk of overtreatment, particularly in the high-risk periocular region.

Contraindications, aftercare, and patient selection

Treatment should be avoided or deferred in the presence of active inflammatory periocular disease, recent isotretinoin use, a history of hypertrophic scarring, or unrealistic expectations.

Post-treatment principles include strict photoprotection, gentle skincare during healing, and monitoring for delayed pigmentary or textural change.

Psychological and quality-of-life considerations

Despite their benign nature, periocular syringomas may cause disproportionate cosmetic distress due to their location in the central facial aesthetic unit. Acknowledging this impact supports empathetic consultation, shared decision-making, and realistic expectation-setting.

Importance for aesthetic and medical practice

Accurate understanding of periocular sweat gland anatomy and syringoma behaviour is essential for safe practice. Misdiagnosis can lead to inappropriate intervention and avoidable complications. An anatomy-led, conservative approach supports patient safety and high-quality outcomes.

References

James WD, Elston DM, Treat JR, Rosenbach MA. Andrews’ Diseases of the Skin. Elsevier.
Elder DE et al. Lever’s Histopathology of the Skin. Wolters Kluwer.
Weedon D. Weedon’s Skin Pathology. Elsevier.
Kang S et al. Fitzpatrick’s Dermatology. McGraw-Hill.
Alsaad KO, Obaidat NA. Eccrine adnexal tumors. Am J Dermatopathol. 2007;29:341–362.
Sánchez Yus E et al. Syringoma: a clinicopathologic study. Am J Dermatopathol. 1997;19:377–384.
Ahn CS, Sangüeza OP. Benign sweat gland tumors. Dermatol Clin. 2017;35:1–14.
Patterson JW. Weedon’s Skin Pathology Essentials. Elsevier.
Habif TP. Clinical Dermatology: A Color Guide to Diagnosis and Therapy. Elsevier.
Zaballos P et al. Dermoscopy of adnexal tumors. Arch Dermatol. 2007;143:1441–1448.
Kim JH et al. Periocular syringomas: clinical features and treatment outcomes. Dermatol Surg. 2015;41:112–118.
Al Aradi IK. Periorbital syringomas in skin of colour. J Cutan Aesthet Surg. 2018;11:92–96.
Grimes PE. Management of hyperpigmentation in darker skin types. Dermatol Clin. 2014;32:283–296.